Please assess the completion status of the following clinical trial:

Trial Title: An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Male or female aged between 20 and 64 years old.~2. Patients diagnosed with partial seizure (including secondarily generalized seizure).~3. Patients who have at least 3 counts of partial seizures during the previous 4 weeks prior to observation start and no seizure-free for 21 days during 8 weeks before the treatment start based on medical records. Simple partial seizure without motor signs will not be counted.~4. Patients who have been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard AED for 2 years.~5. Patients treated with stable doses of up to three AEDs. Only one cytochrome~   P450 (CYP) 3A4 inducer shown below will be allowed for concomitant use:~  * Carbamazepine~  * Phenytoin~  * Phenobarbital~  * Primidone~6. Patients on stable dose of anti-depressants, anti-anxiety drugs, or mood stabilizers from before 8 weeks.~Exclusion criteria:~1. Patients with present or a history of Lennox-Gastaut syndrome.~2. Patients with present generalized seizures (e.g., absence, myoclonic).~3. Patients with a history of status epilepticus within 1 year.~4. Patients with seizure clusters where individual seizure cannot be counted within 8 weeks.~5. Patients with a history of psychogenic seizure.~6. Patients who underwent surgical operation for epilepsy within 2 years.~7. Patients using rescue benzodiazepines at least twice in a 4-week duration within 8 weeks (if 1 or 2 doses over 24-hour period considered one-time rescue).~8. Patients whose alanine aminotransferase (ALT) or aspartate aminotransferase (AST) at enrollment in observation period exceeds 1.5-fold the upper limit of normal (ULN), but those whose ALT or AST are constantly higher than ULN, they can enroll if ALT or AST remain in 3-fold the ULN.~9. Patients with significant active hematological disease; white blood cell (WBC) count \</=2500/uL or neutrophil count \</=1000 uL.~10. Patients on anti-psychotics or who have psychotic disorder and/or psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of suicidal attempt within 2 years.~11. Patients who operate heavy equipment or drive should not be recruited into the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).